Dr Reddy's launches generic anti-viral tablets in US market

Drug firm Dr Reddy's Laboratories has launched generic anti-viral Valganciclovir tablets in the US market.

New Delhi: Drug firm Dr Reddy's Laboratories has launched generic anti-viral Valganciclovir tablets in the US market.

The company has launched Valganciclovir tablets, USP in the strength of 450 mg in the US market on December 15, 2014 and the product has been approved by the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a filing to the BSE today.

The tablets are generic version of Roche's Valcyte tablets, it added.

"The Valcyte tablets brand had US sales of approximately USD 440 million MAT for the most recent twelve months ending in October 2014 according to IMS health," Dr Reddy's said.

Shares of Dr Reddy's Laboratories were today trading at Rs 3,175.60 per scrip in the afternoon trade on the BSE, down 5.32 per cent from its previous close.

By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link

Close